Last reviewed 2026-06-10 · How we verify

Microsatellite Instability-High (MSI-H) Cancer — Treatment Landscape & Competitive Intelligence

Microsatellite Instability-High (MSI-H) Cancer (disease) competitive landscape: 1 marketed treatments tracked, 0 Phase 3 candidates, 0 Phase 2 candidates. Recent regulatory actions and upcoming PDUFA dates across the entire treatment set.

Marketed treatment landscape

Approved drugs treating Microsatellite Instability-High (MSI-H) Cancer, deduplicated by molecule. See the full disease page for line-of-therapy detail.

Phase 3 pipeline

No Phase 3 pipeline candidates tracked.

Phase 2 pipeline

No Phase 2 pipeline candidates tracked.

Recent regulatory actions (last 90 days)

No regulatory actions in the last 90 days for this treatment set.

Upcoming PDUFA dates (next 180 days)

No PDUFA dates in the next 180 days for this treatment set.

Sponsor landscape

1. Pfizer · 1 drug in Microsatellite Instability-High (MSI-H) Cancer

Subscribe to ongoing alerts

Every new regulatory action, PDUFA date, or trial completion in Microsatellite Instability-High (MSI-H) Cancer:

• Microsatellite Instability-High (MSI-H) Cancer treatment updates — RSS
• Microsatellite Instability-High (MSI-H) Cancer treatment updates — Atom
• Microsatellite Instability-High (MSI-H) Cancer treatment updates — JSON

Cite this brief

Drug Landscape (2026). Microsatellite Instability-High (MSI-H) Cancer — Treatment Landscape & Competitive Intelligence Brief. https://druglandscape.com/ci/disease/microsatellite-instability-high-msi-h-cancer. Accessed 2026-06-10.

Related

• Microsatellite Instability-High (MSI-H) Cancer full disease profile — treatment pathway, diagnostics, guidelines
• Browse all CI briefs
• Build a custom feed

Primary sources · FDA · ClinicalTrials.gov · EMA · SEC EDGAR · ChEMBL · Wikidata · full sourcing